Business Overview: Option Care Health, Inc. (Nasdaq: OPCH)

---

Executive Summary

Option Care Health, Inc. is the largest independent provider of home and alternate-site infusion therapy services in the United States. The company delivers IV medications and specialized nursing care directly to patients at home, in ambulatory infusion suites, or in other non-hospital settings, working under the direction of the patient's physician. Option Care Health was formed in 2019 through the merger of Option Care and BioScrip, two of the largest standalone home infusion providers at the time, and is headquartered in Bannockburn, Illinois.

The company operates as a single reportable segment — infusion services — built on more than 40 years of combined clinical experience. As of the end of fiscal 2025 it operated 196 locations across 43 states, including 87 full-service pharmacies and 109 stand-alone ambulatory infusion suites, staffed by more than 5,000 clinicians (pharmacists, nurses, and dietitians), including a dedicated nursing team of roughly 2,700 employees.

Option Care Health matters because it sits at the center of a durable, structural shift in U.S. healthcare: moving complex IV therapies — chemotherapy, anti-infectives, immunoglobulin (IG) infusions, parenteral/enteral nutrition, and more — out of the hospital and into lower-cost home and outpatient settings. In fiscal 2025 the company generated $5.65 billion in net revenue, up 13% year-over-year, and served over 315,000 patients, making it roughly an order of magnitude larger than its next-largest independent, pure-play peers.

---

1. Core Business Model & How They Work

Option Care Health's business model is built around coordinating a clinically complex, physician-directed therapy and delivering it safely outside a hospital or infusion-center setting, at a materially lower cost than inpatient or hospital-outpatient alternatives.

[ Physician Referral ] ➡️ [ Intake / Payer Authorization & Benefits Verification ] ➡️ [ Pharmacy Compounding & Drug Procurement ] ➡️ [ Nursing Coordination & Patient Training ] ➡️ [ In-Home / Ambulatory Suite Infusion Delivery ] ➡️ [ Ongoing Clinical Monitoring & Re-Supply ]

Key Operational Drivers

1. Payer-Reimbursed Service Model: Revenue is generated from third-party payers — managed care organizations, commercial insurers, self-insured employers, Medicare, and Medicaid. Pharmaceuticals are typically reimbursed at a discount to Average Wholesale Price (AWP) or a premium to Average Sales Price (ASP); nursing and other clinical support services are billed separately, often on a per-diem basis.
2. National Pharmacy & Clinical Network: A footprint of 87 full-service pharmacies (73 with attached ambulatory infusion suites) lets Option Care Health compound and dispense complex, often high-cost specialty drugs locally while maintaining consistent national clinical protocols.
3. Clinical Density & Scale: A workforce of 5,000+ clinicians, including a 2,700-person nursing organization supplemented by subcontracted nursing agencies, allows the company to staff visits across a large, dispersed patient population without the fixed-cost burden of a hospital infrastructure.
4. Tuck-In M&A: Beyond organic growth, the company has historically supplemented scale through bolt-on acquisitions (roughly $117 million of cash acquisitions in fiscal 2025 alone) to add local pharmacy density and therapy capabilities.
5. Capital Return: With a largely built-out national footprint, Option Care Health increasingly returns capital to shareholders — the Board authorized a $500 million share repurchase program in January 2025 and expanded it to $1 billion in January 2026; the company repurchased $307 million of stock in fiscal 2025.

---

2. Product Portfolio / Therapy Categories

Option Care Health does not sell discrete "products" in the way a pharma company does — its portfolio is a set of therapy categories, each tied to a chronic or acute clinical need and administered through the same national pharmacy/nursing infrastructure.

---

3. Competitive Landscape

The U.S. home and alternate-site infusion market is large and highly fragmented, per the company's own 10-K characterization, spanning payer-owned specialty pharmacies, large retail/PBM-affiliated infusion units, other independent infusion providers, and thousands of small regional and local operators.

              INFUSION SERVICES COMPETITIVE MAP
   High  ┌──────────────────────────────────────────────┐
         │                                                │
  N      │        [OPTION CARE HEALTH]                   │
  A      │        (Independent, national scale)          │
  T      │                                                │
  I      │   [Amerita / BrightSpring]   [Soleo Health]    │
  O      │                              [KabaFusion]      │
  N      │                              [Vital Care]      │
  A      │                                                │
  L      │  [Optum Infusion Pharmacy] [Coram / CVS Health]│
         │  (Payer/PBM-affiliated, bundled with insurance)│
  S      │                                                │
  C      │               Local / regional independent     │
  A      │               infusion pharmacies & hospital-  │
  L      │               based/outpatient infusion units  │
  E      │                                                │
   Low   └──────────────────────────────────────────────┘
           Low                                        High
                    PAYER / PBM INTEGRATION

• Payer/PBM-affiliated infusion providers — Optum Infusion Pharmacy (UnitedHealth Group), Coram/CVS Specialty Infusion (CVS Health), CVS Caremark, and Optum Rx. These competitors can bundle infusion services into their own insurance book of business and steer patients internally, giving them captive volume even without Option Care Health's clinical scale.
• Other large independent/specialty infusion providers — Amerita Specialty Pharmacy (owned by BrightSpring Health), Soleo Health, KabaFusion, Vital Care, Accredo, and Orsini. These compete on many of the same clinical and geographic dimensions but generally lack Option Care Health's national pharmacy density.
• Hospital-based and hospital-outpatient infusion — the traditional default setting that home infusion displaces; competes less on price (home infusion is typically cheaper) and more on referral-pattern inertia and complex-case capability.
• Regional/local independent pharmacies and ambulatory infusion centers — numerous smaller players that compete on local relationships but cannot match national payer contracting or multi-state clinical consistency.

Notably, Option Care Health's 2023 agreement to acquire Amedisys (a home health and hospice provider) for roughly $3.6 billion was superseded when UnitedHealth Group's Optum made a competing, ultimately successful offer for Amedisys — underscoring how directly Option Care Health competes with payer-owned health-services platforms even in M&A, not just in day-to-day patient referrals.

Competition in the industry is based on quality of care and clinical outcomes, pricing, reputation, and reliability; Option Care Health's own disclosure points to its national presence and marketing reach as a key competitive advantage versus the fragmented regional/local tail of the market.

---

4. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• National Clinical & Pharmacy Density: With 196 locations, 87 pharmacies, and 5,000+ clinicians across 43 states, Option Care Health can offer national payers a single, consistent contracting counterparty with multi-state clinical capability — something few of the fragmented regional/local competitors can match.
• Payer Diversification: No single payer accounted for more than 14% of fiscal 2025 revenue, and direct government programs (Medicare/Medicaid) were only about 12% of revenue — a meaningfully de-risked payer book versus many smaller, geographically concentrated peers.
• Regulatory/Clinical Compliance Scale: Managing compounding pharmacy licensure, nursing credentialing, and payer utilization-management requirements across 43 states is operationally complex; Option Care Health's scale lets it absorb that compliance overhead more efficiently than small regional operators.
• Structural Site-of-Care Tailwind: The secular shift of infusion therapy from hospital to home/alternate-site settings — driven by cost pressure from payers — favors the largest, most trusted independent provider in the category.

Strategic Risks & Vulnerabilities

Reimbursement & Policy Pressure
---------------------------------------------------------------------------
Managed-care contracting   Medicare/Medicaid cuts     IRA drug price cuts
(bid-based pricing)        (sequestration, state      (66% cut to one
                            budget pressure)           therapy's list price,
                                                        effective Jan 2026)

1. Payer Concentration & Bid-Based Contracting: 88% of fiscal 2025 revenue came from managed care organizations and other non-governmental payers. The company explicitly warns that "a rapid concentration of revenue derived from individual managed care payers could harm our business," and that payers often limit the number of approved providers or require competitive bidding that can compress gross margins.
2. Government Reimbursement Pressure: The Inflation Reduction Act (IRA) drove a 66% reduction from the 2023 list price for one therapy in the company's portfolio, effective January 2026; Medicare sequestration cuts of up to 2% annually continue through 2027; and state Medicaid budget pressures add further reimbursement uncertainty.
3. Payment Timing/Liquidity Risk: The company discloses that reimbursement delays "can be significant," which can pressure working capital, cash flow, and reported results in any given period.
4. Supplier Concentration: Roughly 68% of pharmaceutical and medical supply purchases came from just four vendors in fiscal 2025, creating exposure to supply disruption or unfavorable renegotiation.
5. Competitive Disintermediation by Payers: Large payer-affiliated competitors (Optum, CVS/Coram) can internalize infusion volume that would otherwise flow to independent providers like Option Care Health, as demonstrated when Optum outbid Option Care Health for Amedisys in 2023.
6. Margin Compression: Gross margin declined from roughly 20.3% in fiscal 2024 to roughly 19.3% in fiscal 2025 even as revenue grew 13%, consistent with a mix shift toward larger, lower-margin specialty drug volumes and continued payer pricing pressure.

---

5. Financial Overview

---

6. Summary Conclusion

Option Care Health is the clear scale leader in a structurally growing but highly fragmented market: moving complex, physician-directed IV therapy out of expensive hospital settings and into the home. Its moat rests less on patents or brand and more on operational density — a national network of pharmacies, infusion suites, and clinicians large enough to be the default national counterparty for managed-care payers, at a scale that fragmented regional competitors and single-market independents cannot match.

The company's biggest forward risk is the same thing that created its market: payers' control over pricing and access. With 88% of revenue tied to managed care and other non-governmental payers, and direct exposure to bid-based contracting, IRA-driven price cuts, and the possibility that large payer-owned competitors (Optum, CVS/Coram) internalize volume rather than referring it out, Option Care Health's long-term success depends on converting its clinical scale into contracting leverage faster than payers can compress it away.